Mnemosyne Pharmaceuticals

First-in-class subunit-selective NMDA receptor modulators to treat neuropsychiatric diseases, specifically schizophrenia and Alzheimer\'s

Start Free Trial

Start Trial Get Full Profile

There’s no risk. Start your trial today to see profiles of Mnemosyne Pharmaceuticals plus 5267 other startups.

Start Free 7 Day Trial Now

Learn More About Mnemosyne Pharmaceuticals

Technology/product details

Revenue projections

Capital raised to date

Growth strategy

Competing Startups

More

Our Clients

0-Minnetronix.jpg
1-jnj.png
2-medtronic.png
3-abbott.png
4-baxter.png
7-bostonscientific.png
8-bd.png
9-smithnephew.png
10-stryker.png
33m.png
allergan.jpg
bain.jpg
bbraun.png
beckmancoulter.png
cardinal.png
depuysynthes.png
drager.png
edwardslifesciences.png
ethicon.png
ge.png
gore.png
hospira.png
jlabs.jpg
kimberlyclark.png
merck.jpg
olympus.png
orthofix.png
philips.png
sanofigenzyme.png
teleflex.jpg
terumo.png
zimmerbiomet.png